SCHEMBL20125020

SCHEMBL20125020

CC(C)c1cc(Cl)c2nccn2c1

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
NUDT1 P36639 1/20 0.33
TNKS O95271 1/20 0.31
NOTUM Q6P988 1/20 0.31
KCNH2 Q12809 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25749124 0.81 L3MBTL1 (0.42) L3MBTL1NUDT1TNKS
SCHEMBL25527594 0.81 L3MBTL1 (0.59) L3MBTL1NUDT1TNKSKCNH2
SCHEMBL20125017 0.79 L3MBTL1 (0.41) L3MBTL1NUDT1TNKS
SCHEMBL20801915 0.77 L3MBTL1 (0.39) L3MBTL1NUDT1TNKS
SCHEMBL19751463 0.77 L3MBTL1 (0.53) L3MBTL1NUDT1TNKS
SCHEMBL22490650 0.76 L3MBTL1 (0.43) L3MBTL1NUDT1TNKS
SCHEMBL24529216 0.73 L3MBTL1 (0.32) L3MBTL1
SCHEMBL20801724 0.73 METAP2 (0.40) L3MBTL1
SCHEMBL3847774 0.73 L3MBTL1 (0.62) L3MBTL1NUDT1TNKS
SCHEMBL25310547 0.73 NUDT1 (0.45) L3MBTL1NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190077762-A1 QUINOLONE COMPOUND OTSUKA PHARMA CO LTD (JP) 2019-03-14 US disclosed
EP-3318557-A2 QUINOLONE COMPOUND Otsuka Pharmaceutical Co., Ltd. (JP) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077762-A1 QUINOLONE COMPOUND HAX1, NQO2, NHERF1 L3MBTL1 2941/4885NUDT1 1266/4885TNKS 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.